309 results on '"Vakar-Lopez, Funda"'
Search Results
52. Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.
53. Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes
54. Micropapillary urothelial carcinoma (mpUC): A comparative analysis of oncologic outcomes compared to conventional urothelial carcinoma (CUC).
55. Sarcomatoid urothelial carcinoma (SUC): A single-institution experience of oncologic outcomes and recurrence patterns.
56. Method development and feasibility assessment for diagnosing 12 needle cores within an hour of biopsy
57. Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen
58. The Expression of Osteoclastogenesis-Associated Factors and Osteoblast Response to Osteolytic Prostate Cancer Cells
59. Selenium and Vitamin E: Cell Type– and Intervention-Specific Tissue Effects in Prostate Cancer
60. Port-Site Metastasis: The Influence of Biology
61. Treatment outcomes of small cell carcinoma of the prostate: A single-center study
62. Treatment outcomes fo small cell carcinoma of the prostate: a single-center study
63. Histological changes in prostate biopsies after salvage cryotherapy: effect of chronology and the method of biopsy
64. Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy
65. Amplification/Overexpression of a Mitotic Kinase Gene in Human Bladder Cancer
66. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma
67. Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations
68. Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations
69. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
70. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy
71. Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC).
72. Bladder Cancer Multidisciplinary Clinic (BCMC) model: Impact on imaging, pathology and treatment recommendations.
73. PD62-06 DISTINCT GENOMIC HALLMARKS EXIST BETWEEN METASTATIC UPPER AND LOWER TRACT UROTHELIAL CARCINOMA
74. The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells
75. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy
76. HPV16 induces penile intraepithelial neoplasia and squamous cell carcinoma in transgenic mice: first mouse model for HPV‐related penile cancer.
77. Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy
78. MP58-07 MTOR PROTEIN EXPRESSION IN THE TUMOR AND ITS MICROENVIRONMENT CORRELATES WITH MORE AGGRESSIVE PATHOLOGY AT CYSTECTOMY
79. MP54-14 CHARACTERIZATION OF HUMAN BLADDER CANCER PATIENT-DERIVED XENOGRAFT IN VIVO AND IN ORGANOIDS
80. Bladder cancer rapid autopsy: A mechanism for collecting metastatic tumor tissue and establishing xenograft models of metastatic disease.
81. Characterization of human bladder cancer patient-derived xenograft in vivo and in organoids.
82. Correlation of next generation sequencing (NGS) of urine with tumor and plasma in patients with non-muscle invasive bladder cancer (NMIBC).
83. Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort
84. Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports
85. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized
86. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
87. A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer
88. MP37-04 PILOT EVALUATION OF A PATIENT-CENTERED PROSTATE BIOPSY PATHOLOGY REPORT
89. A Novel 4-color Fluorescence in Situ Hybridization Assay for Detection of TMPRSS2 and ERG Rearrangements in Prostate Cancer
90. MP15-20 SURGICAL PATHOLOGY AND THE PATIENT: A SYSTEMATIC REVIEW EVALUATING THE PRIMARY AUDIENCE OF PATHOLOGY REPORTS
91. Surgical pathology and the patient: A systematic review evaluating the primary audience of pathology reports.
92. Association of expression of ERG oncoprotein with development of disease recurrence and prostate cancer-specific mortality.
93. 959 IMMUNOHISTOCHEMICAL EXPRESSION OF ERG ONCOPROTEIN IS ASSOCIATED WITH DEVELOPMENT OF LOCAL RECURRENCE AND PROSTATE CANCER-SPECIFIC DEATH IN MEN TREATED WITH RADICAL PROSTATECTOMY
94. 2112 CORRELATION OF URINE PCA3 SCORE AND TMPRS2:ERG SCORE WITH CLINICALLY SIGNIFICANT TUMOR VOLUME IN RADICAL PROSTATECTOMY SPECIMENS: INTERIM RESULTS FROM A MULTI-CENTER PROSPECTIVE STUDY
95. Radiologic-pathologic findings of solitary fibrous tumor of the prostate presenting as a large mass with delayed filling-in on MRI
96. Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
97. The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment
98. 244 DUCTAL ADENOCARCINOMA OF THE PROSTATE: INCREASED MORTALITY RISK AND DECREASED PSA SECRETION
99. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells
100. The expression of osteoclastogenesis‐associated factors and osteoblast response to osteolytic prostate cancer cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.